H.E. Logue, M.D.

Author Vitae

Author Bio

Author Vitae

Dementia Presentation

Dementia PowerPoint

The Baby Killer Inside

Dissociative Identity Disorder (DID) Article

ADDICTION

Reader Quotes

Foreword

Preface

Excerpt

Addiction PowerPoint

Addiction Resources

FLY ME TO THE MOON

Reader Quotes

Foreword

Preface

Excerpt

CME

Bipolar Disorder PowerPoint

Links

Contact Us

Curriculum Vitae and Resume

Revised 5 July, 2012

H. E. Logue

M.D.

100 Century Park South - Suite 206

Birmingham, AL 35226

Phone: 205-***-****

Fax: 205-***-****

E-Mail: abo024@r.postjobfree.com

Web Site: www.heloguemd.com

CURRENT POSITIONS:

Psychiatrist Private practice Birmingham, July 1972present

Medical Director, Geriatric Behavioral Medicine, Baptist Medical Center, June 2006present

Founder, Chief Medical Officer and Chairman of the Board,

American Behavioral Benefits Managers, a Mental Health managed benefits and EAP company,

October 1989present

Medical Director/FounderBirmingham Psychiatry Pharmaceutical Studies, Inc., November 1992present

President/founder Venture Mental Health Management, a psychiatric consulting and services

company 1987- present

Appointment to Impaired Physicians Assessment and Treatment Panel of Alabama,

1992present

DST Health Solutions, Inc. National UM/QI Committee 20032010

President/founderNovember 1 2004Affiliated Mental Health Services, Inc

. present

PREVIOUS POSITIONS AND EXPERIENCE

Medical Director Chief of Psychiatry Section UAB Medical West 2004April 2006

President (founder July 1972) of Birmingham Psychiatry, P.A. to 2004

Member of Psychiatric Steering Committee Brookwood Medical Center

For Mental Health 19732003

Medical Director, Adult Inpatient Services

Brookwood Medical Center, September 1996July 2003

Medical Director of Development BrookwoodCenter for Mental Health,

October 1987July 2003

Member Brookwood Medical Center Psychiatry Quality Assurance/

Process Improvement Committee,

19862003

Medical Director, Birmingham Chapter, Manic Depressive-Depressive Organization of the

National Organization 1993-2002

Medical Director, Partial Hospital Program,

Brookwood Medical Center, January 19922001

Medical Director for Cebert Pharmaceuticals, Inc, 1997-2000

Founding Board Member and Medical Director of PsychPartners, LLC,

A practice management company 1995July 1998

State Mental Health Director of Correctional System

November 1991October 1994

Public Relations Officer, Alabama Psychiatric Society,

A district branch of the American Psychiatric Association1991-1992

President, Alabama Psychiatric Society (Now Alabama Psychiatric Physicians Association)

1990-1991

Founder of Department of Psychiatry, Brookwood Medical Center,

January 1974. Chairman of Department

from

19741986 (Three four-year terms)

Medical Director, Brookwood Medical Center for Mental Health

September 1, 1985October 1, 1987Member of Executive Committee, Brookwood Medical Center

January 1974December 1986, ex officio member 1986-1987Member of Governing Board of Brookwood Medical Center

Ex officio

1986-1987

Chairman Steering Committee to develop Brookwood s PPO-

Physician s Preferred Provider Comprehensive Health Care Organization

1992-1995

Appointed as

Assistant Professor of Psychiatry to UAB Medical Center1980-1984

Member Divisional Medical Advisory Counsel and Regional Medical Advisory Counsel

American Medical International representing Brookwood Medical Center1983-1988

Member Brookwood Medical Center Long-Range Planning Committee 1983-1988Vice-PresidentCenter for Mental Health Brookwood Hospital

October 1, 1986October 1, 1987

Medical Director, Atlantic Plasma Research Organization1969-1971

HOSPITAL AFFILIATIONS

(1) Brookwood Medical Center

(2) Baptist Medical Center Princeton

(3) St. Vincent s Hospital

EDUCATIONAL BACKGROUND

19691972 Psychiatric Residency at the Medical College of Georgia,

Augusta, Georgia

19631964 One year rotating internship University Hospital,

Augusta, Georgia

1963 Medical College of Georgia, August Georgia M.D. Degree

Graduated Emory University, Atlanta, Georgia, 1958, BA Degree

Associate Degree, Emory at Oxford, Georgia, 1955

Graduated Tennille High School, Washington County, Georgia, 1953

BOARD STATUS AND CERTIFICATIONS

American Board of Psychiatry and Neurology eligible (never sat for Board)

Diplomate of the American Board of Forensic Examiners #9898, 1996

Diplomate of the American Board of Forensic Medicine #9898, 1997

Diplomate and Senior Analyst of American Board of Disability Analysts #42909, 1997

PREPSYCHIATRIC MEDICAL EXPERIENCE

19641969General and family practice North Augusta, South Carolina

Hospital Affiliations

(1)

University Hospital, Augusta, Georgia 1964-1969

(2)

St. Joseph Hospital, Augusta, Georgia 1964-1969

Chief of General Practice Section 1967

HONORS

Distinguished Life Fellow, American Psychiatric Association, January 1, 2012

Named to Best Doctors in America 2011-2012

2007 Named to America s Top Psychiatrists listing by Consumers Research Council

1998 Annual National Exemplary Psychiatrist Award from National Alliance of the Mentally

Ill

1996 Mental Health Professional of the Year Award by Birmingham Alliance for the Mentally

Ill

U.S. Neuroscience Advisory Board Eli Lilly & Co. 1996-1999

Astra-Zenica Regional Advisory Board

Elected member Who s Who Worldwide 1994-1995 Edition,

Lifetime Member

National Registry of Who s Who, 2001 Edition

President, Alabama Psychiatric Society

A district branch of the American Psychiatric Association 1990-1991

1989 1990 President-Elect Alabama Psychiatric Society

Governor s appointment to Medical Advisory Board for Corrective Systems

In Alabama, January 1983-1985

Awarded Honorary Assistant Attorney General Alabama awarded 1983

Elected Secretary of State Chapter Gamma Kappa Alumni Society of Theta Kappa Psi

Medical fraternity 1963-1974

1955 awarded scholastic scholarship to attend Emory University for the following year

March 1955 inducted in Phi Delta Omega Science honor fraternity for premedical and

predental students at Emory at Oxford

PROFESSIONAL ORGANIZATIONS AND MEMBERSHIPS

(1) American Psychiatric Association

(2) American Medical Association (terminated membership 2010)

(3) American College of Physician Executives

(4) Alabama Psychiatric Physicians Association (A District Branch of American Psychiatric

Association)

(5) Jefferson County Medical Society

(6) Medical Association of State of Alabama

(7) Central Alabama Psychiatric Society

(8) The American College of Forensic Medicine (inactive)

(9) The American College of Forensic Examiners (inactive)

(10) The American College of Physician Executives

(11) The American Board of Disability Analysts

MILITARY SERVICE

Enlisted in Army National Guard, 1955, Private E-1,

Transferred to Army Reserves, 1957

Honorable Discharge, 1974, Captain (eligible for Major)

CIVIC AND SECULAR ORGANIZATIONS

Managing Partner, Birmingham Professional Associates I & II

Associates owned POB: 1984-1999 when property was sold.

Served as Coordinator for United Way for psychiatrists of Jefferson County 1987

Member of Board of Advisors for State organization of

Mental Health Technicians1976National Alliance for the Mentally Ill, Birmingham, Alabama

Member of

Board of Birmingham Crisis Center1976-1980 Served as Executive Committee member

1979-1980President, Taino Gardens Condominiums Homeowner s Association

Freeport, Grand Bahama Island, Bahamas 1984Present

Board member, Edgewater Condominium Association Destin, Florida 2001-Present

PUBLICATIONS

Numerous talks at various hospitals and county medical societies on depression and

anxiety.

Talks to department of medicine at Brookwood Medical Center on several occasions on

topics of anxiety, depression, the seductive patient, etc.

Educational Outreach Program. For several years, I presented talks to county medical

societies as an educational outreach program of Brookwood Medical Center, giving

approximately two lectures per year on mental health topics. I am currently doing the same

thing for Baptist Medical Center Princeton.

Presented grand rounds at Brookwood Medical Center Department of Psychiatry several

times, topics including depression, anxiety, the seductive patient, stress, milieu therapy

and others

Talk to South Alabama Psychiatric Society 1991; 50 Years Changes/Progress in Medicine

Talk to Department of Psychiatry, Ochsner Clinic, New Orleans, Louisiana 1993,

Living with Managed Care

National Speaking Circuit regarding New Horizons in Treatment of Schizophrenia

1996 1999, by Pragmaton, a CME organization

Numerous talks to various civic groups including Rotary clubs, churches, Kiwanas, radio

programs and TV appearances (1964 present) covering the following topics:

Psychiatry

Religion

Dreams

Depression

Anxiety

Suicide in youth and prevention

Drug abuse and prevention

Commitment

Success vs. Failure

Hypnosis

Holiday depression

Bipolar Disorder

Schizophrenia

New psychiatric medicines for depression and schizophrenia

New antipsychotic medications; present at several southern cities

Numerous talks to psychiatric communities through the South on the

new atypical antipsychotics

Weight control

Addiction

RESEARCH EXPERIENCE

Principal Investigator

Insomnia treatment study

The Upjohn Company1992

Principal Investigator

Fluvoxamine vs. Placebo in the treatment

of Panic Disorder

Enrolled: 20 patients (6 months) 1992-1993

Principal Investigator

Fluvoxamine vs. Placebo in the treatment of

Panic Disorder: A long-term maintenance,

Double Blind study company efficacy and safety

Enrolled: 20 patients (6 months)

The Upjohn Company/Pharmaco1993-1994

Principal Investigator

A Randomized, comparative open-labeled study

of Paroxetine in the Treatment of Depression as

used in a Clinical Practice Setting

Smith-Kline Beecham/Clin-Trials

Enrolled: 20 patients (3 months) 1993-1994

Principal Investigator

Olanzapine vs. Haloperidol in the Treatment of

Schizophrenia and Other Psychotic Disorders (HGAJ)

Enrolled: 44 patients (12 months)

Eli Lilly/Pharmaco1994-1995Principal Investigator

Imitrex Injections in the Treatment of Migraine Headaches

Enrolled: 40 patients (2 months) 1994

Principal Investigator

Epidemiologic Survey of Prostep

Enrolled: 20 patients 1993-1994

Principal Investigator

A Double-Blind Placebo-controlled, dose response

comparison of the safety and efficacy of three doses

of Sertindole and three doses of Haldol in Schizophrenic

Patients (M930113) Abbott Laboratories Inpatient Study

Enrolled: 34 patients (6 months) 1994-1995

Principal Investigator

An Open-label Assessment of the long-term safety

of Sertindole in the treatment of Schizophrenic patients

(M92-795)

Enrolled: 17 patients (Continuous Study from M93-113)

Abbott Laboratories1995Principal Investigator

An Open-label Assessment of the Safety of Sertindole (M94-222)

Enrolled: 15 patients (Continuation Study from M93-ll3)

Abbott Laboratories1995Principal Investigator

A Phase II comparative study using a single dose of

Acetaminophen, Acetaminophen/Cyproheptadine, Cyproheptadine

Alone and Placebo in the Treatment of Migraine Headache

McNeil Laboratories1994-1995Principal Investigator

A prospective, Multi-center, Open-label study of Serzone

(nefazodone) in the Management of Patients with Symptoms

of Depression in General Psychiatric Practices

(CN 104-127)

Enrolled: 14 patients (3 months)

Bristol-Myers Squibb/ICRC1995Principal Investigator

Olanzapine vs. Risperidone in the Treatment of Schizophrenia

and other Psychotic Disorders (FID-MC-HGBG)

Enrolled: 49 patients (4 months)

Eli Lilly 1995

Sub Investigator

A Multi Center, Placebo-Controlled Study of Relapse Prevention

By Long-Term Treatment with High or Low Doses of ORG-4428

In Outpatients with Recurrent Major Depressive Episode

Enrolled: 35 patients

Organon/Pharmaco

Principal Investigator

Open Label Experience with Olanzapine in Patients Who Have

Completed a Previous Olanzapine Clinical Trial protocol,

(Compassionate Use Study) (HGDI)

Enrolled: 13 patients from previous Olanzapine Studies

Eli LillyFebruary 1996Sub Investigator

A Randomized Double-Blind, Placebo-Controlled parallel group

multicenter, single dose range finding study to assess the

efficacy and tolerability of VML 251 in the acute treatment of migraine

Vanguard Medica Limited/Pharmaco

April 1996 to June 1996Principal Investigator

Mazapertine dose finding trial comparing three fixed dosages

if Mazapertine to Risperidone and placebo: multicenter, double-blind

parallel group study

Janssen Pharmaceutical Research Foundation

March 1996 to July 2, 1996

Inpatient Study Phase II Clinical Trial

Screened: 23 patients Randomized: 20 patients

Principal Investigator

A Comparison of Risperidone and Haloperidol for Prevention

of Relapse in Subjects with Schizophrenia and Schizoaffective Disorders:

Enrolled: 24 patients

Janssen Pharmaceutical Research

Outpatient study

Sub Investigator

An Open-Label, Multicenter Trial Evaluating the Safety

and Efficacy of Donepezil Hydrochloride in Patients with

Alzheimer s Disease

Outpatient

Pfizer PharmaceuticalPrincipal Investigator

A Multi-Center, Double-Blind, Randomized Comparison of

Zolmitriptan and Sumatriptan in the Acute Treatment of

Multiple Migraine Headaches

Outpatient

Zeneca Pharmaceutical

Principal Investigator

A Multi-Center, Double-Blind, Randomized, Placebo Controlled,

Parallel Group Study of the Efficacy and Safety of Escalating

The Dose of Oral Eletriptan in Subjects with Acute Migraine

PfizerPrincipal Investigator

A 12 Month Study of VML251 In the Acute Treatment of Migraine

Vanguard Medical Ltd.

Principal Investigator

A Multi-Center, Randomized, Double-Blind, Placebo and Active

Controlled Study of MDL 100-907 in Schizophrenic and

Schizoaffective Patients

Hoechst Marion Roussel, Inc.

Principal Investigator

A Multi-Center, Open-Label, Long-Term follow-up, Safety

Study of MDL 100-907 in Schizophrenic and Schizoaffective

Patients Who Participated in Protocol 100907 PR0015

Hoeschst Marion Roussel, Inc.

Principal Investigator

A Phase III, Randomized, Multi-Center, Open-Label study

Evaluating the Tolerance and Safety of 3 Days of Treatments

With Intramuscular Ziprasidone (20 to 80 mg. daily) or Haloperidol

(up to 40 mg. daily) followed by 4 days of Treatment with Oral Ziprasidone

(40 to 200 mg. daily) or Haloperidol in subjects with a Diagnosis of Psychotic Disorder

PfizerPrincipal Investigator

Risperidone vs Olanzapine in the Treatment of Schizophrenia

in Elderly Subjects RIS-INT-50

Outpatient Study

Janssen Research Foundation

Principal Investigator

Risperidone vs Olanzapine in the Treatment of Schizophrenia

RIS-USA-112

Principal Investigator

Risperidone vs Olanzapine in the Treatment of Schizophrenia

RIS-USA-113

Principal Investigator

Fluvoxetine Augmentation in Schizophrenic or Schizoaffective

Patients with Depressive or Nonresponders to Olanzapine

FID-MC-HGFT Outpatient study

Eli Lilly

Principal Investigator

Strategies for switching from Conventional Antipsychotic Drugs

to Olanzapine .

FID-MC-HGFW Outpatient study

Eli Lilly

Principal Investigator

Olanzapine Added to Mood Stabilizers in the Treatment of

Bipolar Disorder .

FID-MC-HGFU Outpatient study

Eli Lilly

Sub-Investigator

Metrifonate Investigational Nationwide Trial

(M.I.N.T.) D97-019

Bayer CorporationPrincipal Investigator

The Safety and Efficacy of Risperdal (Risperidone) vs.

Placebo vs. Haloperidol as Add on Therapy to Mood Stabilizers

In the Treatment of the Manic Phase of Bipolar Disorder.

RIS-USA-102 Inpatient/Outpatient

Janssen Pharmaceutical Research Foundation

July 1998Principal Investigator

A Multicenter, Randomized, Double-Blind, parallel Group

Trial Comparing the Safety and Efficacy of Risperidone and

Olanzapine in the Treatment of Psychosis in Patients with

Schizophrenia and Schizoaffective Disorder (9 weeks).

RIS-USA-112 Outpatient Study

Janssen Pharmaceutical Research FoundationNovember 1997-April 1998Principal Investigator

A Multicenter, Randomized, Double-Blind, Parallel Group

Trial Comparing the Safety and Efficacy of Risperidone and

Olanzapine in the Treatment of Psychosis in Patients with

Schizophrenia and Schizoaffective Disorder (44 weeks),

RIS-USA-113 Outpatient Study

Janssen Pharmaceutica Research FoundationDecember 1997Principal Investigator

EMD 68 843

A Double-Blind Randomized, Multicenter, Parallel Design Study to

Evaluation the Efficacy and Safety of Individual Maximum Tolerated

Doses of EMD 68 843 in Comparison with Placebo and Fluoxetine in

Outpatients with Major Depressive Disorder.

Merck KgaA

Outpatient Study April 1998Principal Investigator

Sanofi DFI 3077

A Double-Blind, Placebo and Haloperidol Controlled Multicenter Study

Evaluating the Safety and Efficacy of SR 46349B, Protocol DFI 3024

Or SR 48692, Protocol DFI 3067 or SR 141716, Protocol DFI 3077 or SR 142801,

Protocol DFI 3138 in Schizophrenic Patients .

Sanofi Inpatient/Outpatient Study

September 1998Principal Investigator

ABA 451

A Prospective, Randomized, International, Parallel-Group

Comparison of Clozaril/Leponex vs. Zyprexa in the Reduction of

Suicidality in Patients with Schizophrenia or Schizoaffective Disorder

Who are at Risk for Suicide .

Novartis Outpatient Study

May 1998Principal Investigator

Phase II, Six-Week, Double-Blind, Placebo and Olanzapine-Controlled

Study Evaluating the Safety and Efficacy of Oral CP-361, 428 in

Schizophrenia and Schizoaffective Disorder

Schizophrenia Study

Pfizer 245-102 Inpatient study

PfizerPrincipal Investigator

A Double-Blind, Randomized, Multicenter, Parallel Group Design Study

to Evaluate the efficacy of Two Dose Ranges of EMD 128 130 in

Comparison with Placebo and Haloperidol in the Treatment of Schizophrenia

EMD 128-130-08

Schizophrenia study

Inpatient/Outpatient Study

Merck KgaA Pharmaceutical Co.

Principal Investigator

A Prospective, Randomized, Double-Blind, Placebo and active-controlled,

multicenter study to evaluate the efficacy and safety of three fixed doses

of Iloperidone (4, 8 and 21 mg/d) given b.i.d. for 42 days to schizophrenic

patients with acute or subacute exacerbation, followed by a double-blind,

active-controlled, flexible-dose, long-term, 6-month phase with Iloperidone

(4, 8, 12 or 16 mg/d) given q.d.

ILP 3000 schizophrenia

Inpatient and Outpatient Study

Novartis

Principal Investigator

The Assessment of Nizatidine for the Prevention of Olanzapine-

Associated Weight Gain in Patients with Schizophrenia

HGIJ Outpatient Study

Eli Lilly

Principal Investigator

Protocol: F1D-MC-HGHL

Olanzapine Versus Placebo in the Prevention of Relapse in

Bipolar Disorder

HGIJ Outpatient Study

Eli Lilly

Principal Investigator

Protocol: F1D-MC-HGHL

Oanzapine Versus Placebo in the Prevention of Relapse in

Bipolar Disorder

HGHL Outpatient Study

Eli Lilly

Principal Investigator

Prevalence of Hyperprolactemia in Schizophrenic Patients Treatees

with Antipsychotic Drugs

Prolactin Study

HGHC Outpatient Study

Eli Lilly

Principal Investigator

Allelic Variation in Schizophrenia

HGGL Outpatient Study

Eli Lilly

Principal Investigator

Protocol: F1D-MC-HGHZ

The Combination of Olanzapine and Fluoxetine in

Treatment Resistant Depression without Psychotic

Features

HGHZ Outpatient Study

Eli Lilly

Principal Investigator

Randomized, double-blind, placebo-controlled multicenter trial to

demonstrate the clinical efficacy and safety of two different doses of

Ginko biloba special extract Egb 761 in patients suffering from

Dementia of the Alzheimer s Type according to DSM-IV and

NINCDS/ADRA criteria.

Schwabe Protocol 523***-**-***

Alzheimer s Study

Outpatient study

SchwabePrincipal Investigator

A Double-Blind, Placebo-Controlled Dose-Finding Study Evaluating the

Safety and Efficacy of MKC-242 1.5, 6, and 24 mg/day (0.5, 2, and 8 mg. tid)

the Treatment of Major Depressive Disorder.

MKC/A01

Depression study

Outpatient study

Mitsubishi

Principal Investigator

Safety and Efficacy of MKC-242 in the treatment of Major Depressive Disorder:

A 4 month double-blind extension to study MKC242-A01.

MKC/A02

Depression study

Outpatient study

Mitsubishi

Principal Investigator

Safety of open-label standard therapy in the treatment of Major Depressive

Disorder: A 1 month follow-up after termination of study MKC-242/A01.

MKC/A03

Depression study

Outpatient study

Mitsubishi

Principal Investigator

A Double-Blind, Placebo and Haloperidol-Controlled, Multicenter

Study Evaluating the Safety and Efficacy of SR141716 in Schizophrenic

Patients

Sanofi 3077

Schizophrenia study

Inpatient study

Principal Investigator

Abbott M99-010

Safety and Efficacy of Depakote as Combination Therapy in the Treatment

of Psychosis Associated with Schizophrenia.

Inpatient study

Abbott Laboratories

Inpatient study

Principal Investigator

Protocol No. CN138-070 and CN138-010

A Multicenter, Randomized, Double-Blind, Placebo Controlled Study

of Aripiprazole in the Maintenance Treatment of Patients with Bipolar

Disorder.

Bristol-Myers Squibb Pharmaceutical Research Institute

Inpatient/Outpatient study

Principal Investigator

Protocol No. F1D-MC-HGIJ

The Assessment of Nizatidine for the Prevention of Olanzapine-

Associated Weight Gain in Patients with Schizophrenia.

Outpatient study

Sponsor: Eli Lilly

Principal Investigator

Protocol No. F1J-MC-HMAT

Duloxetine Versus Placebo and Paroxetine in the Acute Treatment of

Major Depression.

Sponsor: Eli Lilly

Principal Investigator

Protocol No. F1D-US-HGJB

A Controlled Trial of Olanzapine Versus Quetiapine in the Treatment

of Schizophrenic and Schizoaffective Subjects with Prominent Negative

Symptoms.

Outpatient study

Sponsor: Eli Lilly

Principal Investigator

Protocol No. F1J-MC-HMBH

Duloxetine Once-Daily Dosing Versus Placebo in the Acute Treatment

of Major Depression.

Outpatient study

Sponsor: Eli Lilly

Principal Investigator

Protocol No. TAK 637-00-302

A Phase II Randomized, Multicenter, Placebo- and Active Controlled

Study of Oral TAK-637 in Subjects with Major Depressive Disorder.

Outpatient Study

Sponsor:

TAP Pharmaceutical Products, Inc.

Principal Investigator

Protocol No. FID-MC-HGGY

Placebo Controlled Olanzapine Monotherapy in the Treatment of

Bipolar I Depression

Outpatient Study

Sponsor: Eli Lilly

Principal Investigator

Protocol No. F1D-MC-HGJN

The Assessment of Amantadine for the Treatment of Olanzapine-

Associated Weight Gain in Patients with Schizophrenia, Schizophreniform,

Schizoaffective and Bipolar I Disorder.

Outpatient Study

Sponsor: Eli Lilly

Principal Investigator

Protocol No. ILP 3005

A randomized, double-blind, placebo- and risperidone controlled

multicenter study to evaluate the efficacy and safety of two nonoverlapping

dose ranges of iloperidone given b.i.d. for 42 days to Schizophrenic patients

followed by a long-term treatment phase with iloperidone given q.d.

Inpatient and outpatient study

Sponsor: Novartis

Principal Investigator

Weight loss Study with carbohydrate restriction to 100 grams per day.

Principal Investigator

A Phase III, Randomized, Placebo-Controlled Study Evaluating the

Safety and Outcome of Treatment with Oral Ziprasidone in subjects

with Mania.

128-601 Inpatient/Outpatient Study

PfizerPrincipal Investigator

An Open Extension Study Evaluating For Safety and outcome of 40-160 mg.

daily of Ziprasidone in Previous Ziprasidone Clinical Trials.

128-601 Inpatient/Outpatient Study

PfizerPrincipal Investigator

A Double-Blind, Randomized, Multicenter, Parallel Design Study to

Evaluate the Efficacy and Safety of Individual Maximum Tolerated Doses

of EMD 68 843 in Comparison with Placebo and Fluoxetine in Outpatients

with Major Depressive Disorder.

Merck EMD Outpatient Study

Merck KgaA

Principal Investigator

Protocol No. D105006

A Double-Blind, Randomized, Fixed Dose, Placebo-Controlled, Parallel-Group

6-Week, Efficacy, Safety, and Tolerability Study of Two Dose Levels of

SM-13496 in Patients with Schizophrenia by DSM-IV Criteria Who Are

Experiencing an Acute Exacerbation of Symptoms.

Sponsor: Sumitomo

Inpatient/Outpatient Study

Principal Investigator

Protocol No. 5077US/0043

A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of

Quetiapine Fumarate (SEROQUEL) and Risperidone (RISPERDAL) in the Treatment of

Patients with Schizophrenia.

Sponsor: AstraZeneca

Inpatient/Outpatient Study

Principal Investigator

B99.CT3.005.BUS P02

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Fixed-Dose

Study of the Efficacy, Safety, and Tolerability of 60 mg Buspirone

Hydrochloride Extended Release Compared to Placebo in Patients with

Generalized Anxiety Disorder

Sponsor: Biovail

Outpatient Study

Principal Investigator

An Open-Label Study of the Safety, and Tolerability, and Efficacy of Up to

90 mg Buspirone Hydrochloride Extended Release in Patients with Generalized

Anxiety Disorder.

B99.CT#3.008.BUS P02

Sponsor: Biovail

Outpatient Study

Principal Investigator

Protocol #: Biovail B01.016.BUS P02

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-

Dose Study of the Efficacy, Safety, and Tolerability of 60 mg Buspirone

Hydrochloride Extended Release Compared to Placebo in Patients with

Generalized Anxiety Disorder Who Have Stable Disease Characteristics.

Sponsor: Biovail

Outpatient Study

Principal Investigator

Protocol:

An Acute and Continuation Phase Study of the Comparative Efficacy

of Venlafaxine ER (Effexor XR) and Fluoxetine (Prozac) in

Achieving and Sustaining Remission (Wellness) in Patients with

Recurrent Unipolar Major Depression; Followed by a Long-term

Randomized, Placebo-Controlled Maintenance Treatment Study in

Patients Treated Initially with Venlafaxine ER

Sponsor: Wyeth-Ayerst Pharmaceuticals

Outpatient Study

Principal Investigator

Protocol:

An International, Multicenter, Large Simple Trial (LST) To Compare

the Cardiovascular Safety of Ziprasidone and Olanzapine

Sponsor:

Pfizer, Inc.

Outpatient Study

Principal Investigator

Protocol: D1050049

A 6-Week, Double-Blind, Randomized, Fixed-Dose, Parallel-Group

Study of the Efficacy and Safety of Three Dose Levels of SM-13496

Compared to Placebo and Haloperidol in Patients with Schizophrenia Who

Are Experiencing an Acute Exacerbation of Symptoms

Sponsor: Sumitomo Pharmaceuticals America, Ltd.

Inpatient/Outpatient Study

Principal Investigator

Protocol: D1050174

An Open-Label, Dose Blinded, Multicenter, 6 Month Study of Safety and

Tolerability of 3 Dose Levels of SM-13496 in Patients with Schizophrenia

Sponsor: Sumitomo Pharmaceuticals America, Ltd.

Outpatient Study

Principal Investigator

Protocol:

A Phase III, Randomised, Placebo-Controlled, Double-Dummy Study

Evaluating the Safety and Efficacy of Oral Ziprasidone vs. Haloperidol

And Placebo in In-Patients with an Acute Manic Episode

Sponsor:

Pfizer Inc.

Inpatient/Outpatient Study

Principal Investigator

Protocol:

A Phase III, Three-Week, Multicenter, Randomized, Double-Blind,

Placebo-Controlled, Parallel-Group Safety and Efficacy Study of

Extended-Release Carbamazepine in the Treatment of Bipolar Disorder

Sponsor: Shire Pharmaceutical Development Inc.

Inpatient/Outpatient Study

Principal Investigator

Protocol:

A Pilot Study of the Effect of Hormone Replacement Therapy In

Recently Postmenopausal Women with Subjective Complaints

Sponsor: Wyeth Pharmaceuticals Inc.

Outpatient Study

Principal Investigator

Protocol: 190-052

Depression Response to Eszopiclone in Adults with Major Depressive

Disorder: A Randomized, Double-Blind, Placebo-Controlled, Parallel-

Group, 8-Week, Safety and Efficacy Study of Eszopiclone 3 mg

Compared to Placebo in Subjects with Insomnia Related to Major

Depressive Disorder

Sponsor: Sepracor

Outpatient Study

Principal Investigator

Protocol: R209130-SCG-202

A Randomized, Double-Blind, Placebo-Controlled, Dose-Response

Study of R209130 in Subjects with Schizophrenia Who Have

Predominantly Negative Symptoms

Sponsor:

Johnson & Johnson

Inpatient/Outpatient Study

Principal Investigator

Protocol: D1447C00135

A Confirmatory Multicenter, Double-Blind, Randomized, Placebo-

Controlled Study of the Use of Quetiapine Fumarate (SEROQUEL) in

the Treatment of Patients with Bipolar Depression

Sponsor: Astra-Zeneca

Outpatient Study

Principal Investigator

Protocol: D1447C00127

A Multicenter, Randomized, Parallel-Group, Double-Blind, Phase III

Comparison of the Efficacy and Safety of Quetiapine Fumarate (oral

Tablets 400 mg to 800 mg daily in divided doses) to Placebo When Used as

Adjunct to Mood Stabilizers (Lithium or Divalproex) in the

Maintenance Treatment of Bipolar Disorder in Adult Patients

Sponsor: Astra-Zeneca

Outpatient Study

Principal Investigator

Protocol: D1444C00133

A 6-week, Multicenter, Double-blind, Double-dummy, Randomized

Comparison of the Efficacy and Safety of Sustained-Release

Formulation Quetiapine Fumarate (SEROQUEL) and Placebo in the

Treatment of Acutely Ill Patients with Schizophrenia

Sponsor: Astra-Zeneca

Outpatient Study

Principal Investigator

Protocol: R076477-SCH-304/704

A Randomized, Double-Blind, Placebo- and Active-Controlled,

Parallel-Group, Dose-Response Study to Evaluate the Efficacy and

Safety of Two Fixed Dosages of Extended Release OROS

Paliperidone (6 and 12 mg/day) and Olanzapine (10 mg/day) with

Open-label Extension, in the Treatment of Subjects with

Schizophrenia

Sponsor:

Johnson & Johnson

Inpatient/Outpatient Study

Principal Investigator

Protocol: F1J-MC-HMDT

Duloxetine Hydrochloride Once Daily Compared with Placebo

in the Treatment of Generalized Anxiety Disorder

Sponsor: Eli Lilly

Outpatient Study

Principal Investigator

Protocol: A1281136

A Six-Week, Randomized, Double-Blind, Multicenter, Fixed-

Flexible Dose, Placebo-Controlled Study Evaluating the Efficacy

and Safety of Oral Ziprasidone in Outpatients with Bipolar I

Depression

Sponsor:

Pfizer Inc.

Outpatient Study

Principal Investigator

Protocol: R092670-PSY-3005; Phase 3

A Randomized, Crossover Study to Evaluate the Overall Safety and

Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus

Muscle in Subjects with Schizophrenia

Sponsor: Johnson & Johnson

Outpatient Study

Principal Investigator

Protocol: 190-902

The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects with

Insomnia Related to Generalized Anxiety Disorder (GAD)

Sponsor: Sepracor

Outpatient Study

Principal Investigator

Protocol: SGS518-CL03

A double-blind, placebo-controlled, dose-ranging, parallel-group study in adults

with cognitive impairment associated with schizophrenia (CIAS)

Sponsor: Saegis

Outpatient Study

89. Principal Investigator:

Protocol: D1444KC0002

"A Multicenter, Double-Blind, Randomized, Parallel-group, Placebo-controlled and

Active-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate

Sustained-release (SEROQUEL) as Monotherapy in the Treatment of Patients with

Major Depressive Disorder (Diamond Study)

Sponsor: AstraZeneca

Outpatient Study

90. Principal Investigator:

Protocol: D14448C0010

"A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Active-

Controlled Study of the Efficacy and Safety of Sustained-release Quetiapine Fumarate

(SEROQUEL) Compared with Placebo in the Treatment of generalized Anxiety

Disorder" (Gold Study)

Sponsor: AstraZeneca

Outpatient Study

91. Principal Investigator

Protocol: A7501013

"A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and

Safety of Asenapine with Olanzapine in Stable Subjects with Predominant, Persistent

Negative Symptoms of Schizophrenia"

Sponsor: Pfizer/Organon

Outpatient Study

92.

Principal Investigator

Protocol: A7501014

"A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing Safety

and Efficacy and of Asenapine with Olanzapine in Subjects who Completed Protocol

A750113"

Sponsor: Pfizer/Organon

Outpatient Study

93.

Principal Investigator

Protocol: A1281136

"A Six-Week, Randomized, Double-Blind, Multicenter, Fiwd-Flexible Dose, Placebo-

Controlled Study Evaluating the Efficacy and Safety of Oral Ziprasidone in Outpatients

with Bipolar I Depression"

Sponsor:

Pfizer Inc.

Outpatient Study

94. Principal Investigator

Protocol: 190-904

"A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly Subjects with

Primary Chronic Insomnia"

Sponsor: Sepracor

Outpatient Study

95.

Principal Investigator

Protocol: EFC5116

"An eight week multicenter, double-blind, placebo- and escitalopram-controlled study

evaluating the efficacy and tolerability of two fixed doses of SSR149415 (250 mg bid

and 100 mg bid) in outpatients with major depressive disorder"

Sponsor: (Sanofi-Aventis)

Outpatient Study

96. Principal Investigator

Protocol: DVS SR 3151A1-403

"A Multicenter, Randomized, 8-Week, Double-Blind, Placebo-Controlled Study

Followed by a 6-Month, Open-label Extension to Evaluate the Efficacy and Safety of

DVS SR in Peri- and Post-Menopausal Women with Major Depressive Disorder"

Sponsor: Wyeth

Outpatient Study

97.

Principal Investigator

Protocol: S154.3.020

"A Multicenter, open-label, parallel-group, randomized, flexible dose study to evaluate

the safety and tolerability of switching from existing atypical antipsychotics to

bifeprunox in subjects with schizophrenia or schizoaffective disorder

Sponsor: Solvay

98. Principal Investigator

Protocol: D144CC00002

"A Multicenter, Double-Blind, Randomized, Parallel-group, Placebo-Controlled, Phase

III Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel) Sustained-

Release as Monotherapy in Adult patients

Sponsor: AstraZeneca

99. Principal Investigator

Protocol: LTE6673

"Efficacy and Safety of 2mg/day of Ml00907 on Sleep Maintenance Insomnia with a

sub-study of the effect of M100907 on stable Type II Diabetes Mellitus: a One Year,

multi-center, randomized, double-blind, placebo-controlled study"

Sponsor: Sanofi-Aventis

100. Principal Investigator

Protocol: CAGO178A2302

Novartis Protocol Entitled: An 8-week, randomized, fixed-dosage, placebo-

controlled, parallel-group, multi-center study of the efficacy, safety and

tolerability of agomelatine 25 and 50 mg in the treatment of Major Depressive

Disorder (MDD)

101. Principal Investigator

Protocol: R092670-PSY-3006

A Randomized, Double-Blind, Parallel Group Comparative Study of

Paliperidone Palmitate (50 mg eq.) and Risperdal CONSTA (25 mg) in Subjects with

Schizophrenia

102. Principal Investigator

Protocol: D1140C00006

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Efficacy

and Safety Study of AZD7325 in the Treatment of Generalized Anxiety Disorder (GAD)

103. Principal Investigator

Protocol: RG2417-03

A Phase II Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess

the Safety, Tolerability and Efficacy of RG2417 (Uridine) in Bipolar I Depression

104. Principal Investigator

Protocol: 3151A1-4415-NA

A Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate 50 mg of

Desvenlafaxine (Pristiq) Extended Release in Functionally Impaired Patients with Major

Depressive Disorder

105. Principal Investigator

Protocol: H9P-MC-LNBI

A Randomized, Double Blind Comparison of LY2216684 and Placebo and Long Term Treatment

with LY2216684 in Adult Patients with Major Depressive Disorder

106. Principal Investigator

Protocol: 3151A1-4437-US

A Randomized, Double-Blind, Parallel Group Study to Compare Discontinuation Symptoms in

Abrupt Discontinuation Versus a 1-Week Tapering Regimen in Subjects with Major Depressive

Disorder (MDD) Treated for 24 Weeks with Open-Label 50 mg Desvenlafaxine Succinate

Sustained-Release Formulation (DVS-SR)

107. Principal Investigator

Protocol: 3151A1-3364-US

A Multicenter, Parallel-Group, Randomized, 10-Week, Double-Blind, Placebo-Controlled

Study to Evaluate the Efficacy and Safety of 50 mg of Desvenlafaxine Succinate Sustained-

Release Formulation (DVS-SR) in the Treatment of Peri- and Post-Menopausal Women with

Major Depressive Disorder

108. Principal Investigator

Protocol: C10953/3072

A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the

Efficacy and Safety Armodafinil Treatment (150 mg and 200 mg/day) as Adjunctive Therapy in

Adults with Major Depression Associated with Bipolar I Disorder

109. Principal Investigator

Protocol: C10953/3074

A 6-Month, Open-Label, Flexible-Dosage (150 mg and 200 mg/day) Extension Study of the

Safety and Efficacy of Armodafinil as Adjunctive Therapy in Adults with Major Depression

Associated with Bipolar I Disorder

110. Principal Investigator

Protocol: CAGO178C2301

An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter

Study of the Efficacy and Safety of Agomelatine 0.5 mg and 1.0 mg Sublingual Tablets in

Patients with Major Depressive Disorder (MDD)

111. Principal Investigator

Protocol: AZD7268

A Phase IIa, Multicenter, Randomized, Double-Blind, D

ptake Inhibitor-

Induced Sexual Dysfunction

Sponsor: Takeda

Copyright 2008. No part of this web site may be reproduced in any fas

Contact this candidate